-+ 0.00%
-+ 0.00%
-+ 0.00%

MedMira Gets FDA Breakthrough Device Designation for Syphilis Test

PUBT·11/17/2026 11:30:43
Listen to the news
MedMira Gets FDA Breakthrough Device Designation for Syphilis Test
  • MedMira received FDA Breakthrough Device Designation for its Multiplo Complete Syphilis (TP/nTP) Antibody Test on November 17, 2026.
  • The rapid test uses proprietary Rapid Vertical Flow technology to detect treponemal and non-treponemal antibodies simultaneously from one fingerstick blood sample.
  • Results are visually interpreted without specialized instruments, potentially expanding access to testing in settings with limited laboratory services.
  • The designation may provide prioritized FDA interaction during development but does not constitute US marketing clearance or approval.
  • The FDA also invited the developer to apply for its Total Product Life Cycle Advisory Program pilot to support clinical and regulatory development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedMira Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611170630ACCESSWRNAPR_____1252536) on November 17, 2026, and is solely responsible for the information contained therein.